Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats

Chemico-Biological Interactions

Volumn 179, Issue 2-3, 2009, Pages 233-239

  Kapetanovic, Izet M ^a   Bauer, Kenneth S ^b   Tessier, Daniel M ^c   Lindeblad, Matthew O ^c   Zakharov, Alexander D ^c   Lubet, Ronald ^a   Lyubimov, Alexander ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aspirin; Chemoprevention; Colon; Pharmacodynamics; Pharmacokinetics; Prostaglandin E2; Salicylate; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN E2; SALICYLIC ACID; THROMBOXANE B2;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; DRUG TISSUE LEVEL; FEEDING; FOOD INTAKE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUANTITATIVE ANALYSIS; RAT;

ADMINISTRATION, ORAL; ANIMALS; ASPIRIN; COLON; DIET; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, INBRED F344; SALICYLATES; THROMBOXANE B2; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 62549099521     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.10.008     Document Type: Article

References (29)

1. Hennekens C.H. Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. Curr. Atheroscler. Rep. 9 5 (2007) 409-416
2. Patrono C., and Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler. Thromb. Vasc. Biol. 28 3 (2008) s25-s32
3. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., and van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348 10 (2003) 891-899
4. Benamouzig R., Uzzan B., Little J., and Chaussade S. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. Curr. Top. Med. Chem. 5 (2005) 493-503
5. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94 4 (2002) 252-266
6. Mahmud S.M., Tanguay S., Begin L.R., Franco E.L., and Aprikian A.G. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur. J. Cancer Prev. 15 2 (2006) 158-164
7. Jacobs E.J., Thun M.J., Bain E.B., Rodriguez C., Henley S.J., and Calle E.E. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl. Cancer Inst. 99 8 (2007) 608-615
8. Sclabas G.M., Uwagawa T., Schmidt C., Hess K.R., Evans D.B., Abbruzzese J.L., and Chiao P.J. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103 12 (2005) 2485-2490
9. Crowell J.A., and Holmes C.J. Agent identification and preclinical testing. Cancer Treat. Res. 106 (2001) 1-30
10. Kapetanovic I.M., Krishnaraj R., Martin-Jimenez T., Yuan L., van Breemen R.B., and Lyubimov A. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics. Chemico-biol. Interact. 164 1-2 (2006) 68-75
11. Li H., Schut H.A., Conran P., Kramer P.M., Lubet R.A., Steele V.E., Hawk E.E., Kelloff G.J., and Pereira M.A. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20 3 (1999) 425-430
12. Reddy B.S., Rao C.V., Rivenson A., and Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14 8 (1993) 1493-1497
13. Vane J.R., and Botting R.M. The mechanism of action of aspirin. Thrombosis Res. 110 5-6 (2003) 255-258
14. Bailer A.J. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharm. Biopharm. 16 3 (1988) 303-309
15. Wientjes M.G., and Levy G. Nonlinear pharmacokinetics of aspirin in rats. J. Pharmacol. Exp. Ther. 245 3 (1988) 809-815
16. Drew J.E., Arthur J.R., Farquharson A.J., Russell W.R., Morrice P.C., and Duthie G.G. Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon. Biochem. Pharmacol. 70 6 (2005) 888-893
17. Lee E.J., Park H.G., and Kang H.S. Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK. Int. J. Oncol. 23 2 (2003) 503-508
18. Wu K.K. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot. Essent. Fatty Acids 72 2 (2005) 89-93
19. McDade T.P., Perugini R.A., Vittimberga Jr. F.J., Carrigan R.C., and Callery M.P. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J. Surg. Res. 83 1 (1999) 56-61
20. Perugini R.A., McDade T.P., Vittimberga Jr. F.J., Duffy A.J., and Callery M.P. Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J. Gastrointest. Surg. 4 1 (2000) 24-32 (discussion 32-33)
21. Vittimberga Jr. F.J., McDade T.P., Perugini R.A., and Callery M.P. Sodium salicylate inhibits macrophage TNF-alpha production and alters MAPK activation. J. Surg. Res. 84 2 (1999) 143-149
22. Paterson J.R., and Lawrence J.R. Endogenous salicylates, aspirin, and inflammation. Arch. Intern. Med. 162 13 (2002) 1531-1532
23. Law B.K., Waltner-Law M.E., Entingh A.J., Chytil A., Aakre M.E., Norgaard P., and Moses H.L. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J. Biol. Chem. 275 49 (2000) 38261-38267
24. Ghezzo F., Cesano L., Mognetti B., Pesce E., Pirro E., Corvetti G., Berta G.N., Zingaro B., and Di Carlo F. Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration. Int. J. Oncol. 26 3 (2005) 697-702
25. Shtivelband M.I., Juneja H.S., Lee S., and Wu K.K. Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J. Thromb. Haemost. 1 10 (2003) 2225-2233
26. Huntjens D.R., Danhof M., and Della Pasqua O.E. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford, England) 44 7 (2005) 846-859
27. Sample D., Wargovich M., Fischer S.M., Inamdar N., Schwartz P., Wang X., Do K.A., and Sinicrope F.A. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol. Biomarkers Prev. 11 3 (2002) 275-279
28. Lora M., Morisset S., Menard H.A., Leduc R., and de Brum-Fernandes A.J. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin, and aspirin. Prostagalndins Leukot. Essent. Fatty Acids 56 (1997) 361-367
29. Grubbs C.J., Steele V.E., Juliana M.M., et al. Chemopreventive effects of Iressa, aspirin, and resveratrol against OH-BBN induced urinary bladder tumors. AACR Annual Meeting (2007) (Abstract 3376)